Display options
Cite
Meng Y, Liao YB, Xu P, et al. Statin use and mortality of patients with prostate cancer: a meta-analysis. Onco Targets Ther. 2016;9:1689-96doi: 10.2147/OTT.S97993.
Meng, Y., Liao, Y. B., Xu, P., Wei, W. R., & Wang, J. (2016). Statin use and mortality of patients with prostate cancer: a meta-analysis. OncoTargets and therapy, 91689-96. https://doi.org/10.2147/OTT.S97993
Meng, Yang, et al. "Statin use and mortality of patients with prostate cancer: a meta-analysis." OncoTargets and therapy vol. 9 (2016): 1689-96. doi: https://doi.org/10.2147/OTT.S97993
Meng Y, Liao YB, Xu P, Wei WR, Wang J. Statin use and mortality of patients with prostate cancer: a meta-analysis. Onco Targets Ther. 2016 Mar 21;9:1689-96. doi: 10.2147/OTT.S97993. eCollection 2016. PMID: 27051303; PMCID: PMC4807937.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2016 Mar 21;9:1689-96. doi: 10.2147/OTT.S97993. eCollection 2016.

Statin use and mortality of patients with prostate cancer: a meta-analysis.

OncoTargets and therapy

Yang Meng, Yan-Biao Liao, Peng Xu, Wu-Ran Wei, Jia Wang

Affiliations

  1. Department of Urology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
  2. Department of Cardiology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.

PMID: 27051303 PMCID: PMC4807937 DOI: 10.2147/OTT.S97993

Abstract

OBJECTIVE: The aim of this meta-analysis was to investigate the effect of statin use on the mortality of patients with prostate cancer (PCa).

METHODS: An electronic search of PubMed, Embase, and CENTRAL databases from inception to August 2015 was performed to find eligible studies. Articles investigating the association between statin use and mortality of PCa were identified. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using random- or fixed-effects models.

RESULTS: In total, 13 studies that enrolled 100,536 participants were included in this meta-analysis. Results showed that prediagnostic statin use had a significantly lower risk of both all-cause mortality (ACM; HR, 0.56; 95% CI, 0.38-0.83) and PCa-specific mortality (PCSM; HR, 0.53; 95% CI, 0.36-0.77). Similarly, postdiagnostic statin use was correlated with reductions in both ACM (HR, 0.77; 95% CI, 0.69-0.87) and PCSM (HR, 0.64; 95% CI, 0.52-0.79). When stratified by primary treatment, postdiagnostic use of statins had a 0.4-fold lower risk of ACM in patients with PCa who were treated with local therapy; both pre- and postdiagnostic use of statins was correlated with a significantly lower risk of PCSM in patients who were treated with androgen deprivation therapy.

CONCLUSION: Both pre- and postdiagnostic use of statins is associated with better overall survival and PCa-specific survival. This suggests a need for randomized controlled trials of statins in patients with PCa.

Keywords: all-cause mortality; prostate cancer; prostate cancer-specific mortality; statins

References

  1. Am J Med. 1998 Feb 23;104(2A):2S-5S - PubMed
  2. Oncol Rep. 2014 Oct;32(4):1727-33 - PubMed
  3. Prostate. 2013 Aug;73(11):1214-22 - PubMed
  4. J Biol Chem. 1996 Jul 19;271(29):17453-62 - PubMed
  5. Int J Oncol. 2005 Nov;27(5):1401-9 - PubMed
  6. Can J Urol. 2015 Apr;22(2):7703-8 - PubMed
  7. Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E74-81 - PubMed
  8. BJU Int. 2013 May;111(6):954-62 - PubMed
  9. BMC Med Res Methodol. 2014 Apr 01;14:45 - PubMed
  10. Prostate Cancer. 2014;2014:184297 - PubMed
  11. BJU Int. 2010 Sep;106(5):627-32 - PubMed
  12. BMJ. 2009 Jul 21;339:b2700 - PubMed
  13. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  14. EMBO Mol Med. 2015 Sep 27;7(11):1450-64 - PubMed
  15. Cancer. 2012 Aug 15;118(16):4046-52 - PubMed
  16. PLoS One. 2012;7(10):e46691 - PubMed
  17. N Engl J Med. 2012 Nov 8;367(19):1792-802 - PubMed
  18. J Clin Oncol. 2014 Jan 1;32(1):5-11 - PubMed
  19. Am J Cancer Res. 2011;1(4):542-61 - PubMed
  20. Eur J Cancer. 2011 Apr;47(6):819-30 - PubMed
  21. Eur Urol. 2015 Jun;67(6):1122-33 - PubMed
  22. Clin Cancer Res. 2003 Jan;9(1):10-9 - PubMed
  23. Curr Cancer Drug Targets. 2005 Dec;5(8):579-94 - PubMed
  24. Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1638-40 - PubMed
  25. Leukemia. 2002 Apr;16(4):508-19 - PubMed

Publication Types